Pulse Biosciences (NASDAQ:PLSE) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Pulse Biosciences (NASDAQ:PLSE) released its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.04, Fidelity Earnings reports.

NASDAQ:PLSE traded up $0.08 during mid-day trading on Friday, hitting $14.39. 63,300 shares of the company’s stock traded hands, compared to its average volume of 56,101. The firm has a 50 day moving average of $14.95 and a two-hundred day moving average of $13.25. Pulse Biosciences has a 12 month low of $9.52 and a 12 month high of $19.77. The firm has a market capitalization of $306.54 million, a price-to-earnings ratio of -6.54 and a beta of 1.84. The company has a current ratio of 12.92, a quick ratio of 12.92 and a debt-to-equity ratio of 0.07.

Several analysts have recently issued reports on PLSE shares. ValuEngine upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th. BidaskClub downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

Recommended Story: Using other technical indicators with support levels

Earnings History for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit